CDK4 and neoplasm: The promises and dangers surrounding the combined use of CDK4/6 inhibitors and cytotoxic chemotherapeutics are discussed at length in this review (Roberts et al, 2020), which contains details of the different tumour types that have been shown to benefit from this approach.